Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Markus F. Renschler"'
Autor:
Ronald L. Korn, Daniel D. Von Hoff, Mitesh J. Borad, Markus F. Renschler, Desmond McGovern, R. Curtis Bay, Ramesh K. Ramanathan
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background Positron emission tomography (PET) is poised to become a useful imaging modality in staging and evaluating therapeutic responses in patients with metastatic pancreatic cancer (mPC). This analysis from a phase 1/2 study examined th
Externí odkaz:
https://doaj.org/article/716747d98fa044a3b00ee009aff4ab2a
Autor:
Daniel D Von Hoff, Markus F Renschler
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Externí odkaz:
https://doaj.org/article/e065780b4a074f429dc4a3f537897f5a
Autor:
Johanna C. Bendell, Martin Gutierrez, Neil Palmisiano, Manish R. Patel, Ranjana H. Advani, Monika L. Burness, Susan Doleman, William D. Bradley, Timothy A. Yap, Judson Englert, Markus F. Renschler, Gerald Steven Falchook, Mehdi Hamadani, Ryan C. Lynch, Pamela N. Munster, Thomas J O'Shea
Publikováno v:
Journal of Clinical Oncology. 39:3006-3006
3006 Background: Homologous recombination (HR) is an essential, high-fidelity mechanism to repair DNA double strand breaks (DSBs). Inhibition of HR in cancer cells leads to accumulation of unrepaired DSBs and tumor cell death. This is the first repor
Autor:
Bruce E. Dornseif, Mingyu Li, Qiang Xu, Gary G. Koch, Guang Chen, Xiaolong Luo, Markus F. Renschler, Chengqing Wu
Publikováno v:
Journal of Biopharmaceutical Statistics. 26:790-800
Clinical trials that explore long-term endpoints may confound the analysis when post-study therapy effects are considered. This article introduces a procedure to mediate the effects of confounding and allow inferences of first-line experimental treat
Autor:
David Goldstein, Elena G. Chiorean, Ramesh K. Ramanathan, Michele Reni, Daniel D. Von Hoff, Marc F. Botteman, Abdalla Aly, Chee Lee, Desmond McGovern, Brian Lu, Josep Tabernero, Sandra Margunato-Debay, Julia Wilkerson, Chrystal U. Louis, Markus F. Renschler
Publikováno v:
Annals of Oncology. 28:iii142-iii144
Autor:
Daniel D Von Hoff, Markus F Renschler
Publikováno v:
Therapeutic Advances in Medical Oncology. 9:441-443
Autor:
Fang-Ju Lin, Corey J. Langer, Teng Jin Ong, Yin Wan, Scott Whiting, Marc F. Botteman, Markus F. Renschler, Vera Hirsh, Isamu Okamoto
Publikováno v:
British Journal of Cancer
Background: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCL
Autor:
Mark A. Socinski, Isamu Okamoto, J. Orsini, Hiroshi Sakai, Hui Zhang, Ray D. Page, Jeremy K. Hon, Vera Hirsh, Markus F. Renschler
Publikováno v:
Journal of Thoracic Oncology. 9(1):83-90
Introduction:nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced non–small-cell lung cancer, based on a randomized phase 3 trial of nab-P plus carboplatin (nab-P/C) vers
Publikováno v:
Therapeutic Advances in Medical Oncology
Autor:
Helen Liu, Stefano Ferrara, Markus F. Renschler, David Goldstein, Volker Kunzmann, Ramesh K. Ramanathan, Daniel D. Von Hoff, Brian Lu
Publikováno v:
Pancreas
Objectives Results from the phase 3 Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) led to approval of nab-paclitaxel plus gemcitabine for first-line treatment of metastatic pancreatic cancer. The current analysis evaluated the effects of